section name header

Pronunciation

tran-ill-SIP-roe-meen

Classifications

Therapeutic Classification: antidepressants

Pharmacologic Classification: monamine oxidase inhibitors

Indications

REMS


Action

  • Inhibits the enzyme monoamine oxidase, resulting in an accumulation of various neurotransmitters (dopamine, epinephrine, norepinephrine, and serotonin) in the body.
Therapeutic effects:
  • Improved mood in depressed patients.

Pharmacokinetics

Absorption: Unknown.

Distribution: Crosses the placenta and enters breast milk.

Metabolism/Excretion: Unknown.

Half-Life: 90–190 min.

Time/Action Profile

(antidepressant effect)

ROUTEONSETPEAKDURATION
PO2 days-3 wk2–3 wk3–5 days





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: edema, HYPERTENSIVE CRISIS, orthostatic hypotension, tachycardia

Derm: alopecia, rash

EENT: blurred vision, tinnitus

Endo: hypoglycemia

GI: abdominal pain, anorexia, constipation, diarrhea, dry mouth, HEPATOTOXICITY, nausea

GU: sexual dysfunction, urinary retention

Hemat: AGRANULOCYTOSIS, leukopenia, thrombocytopenia

MS: muscle spasm

Neuro: confusion, dizziness, drowsiness, headache, insomnia, paresthesia, restlessness, SEIZURES, tremor, weakness

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Parnate